Pulmonary arterial hypertension (PAH) is an enigmatic and deadly vascular disease with no
known cure. Recent years have seen rapid advances in our understanding of the molecular …

Pulmonary arterial hypertension (PAH) is more prevalent in females. Paradoxically, female
patients have better right ventricular (RV) function and higher survival rates than males …

17β-estradiol (E2) exerts complex and context-dependent effects in pulmonary
hypertension. In hypoxia-induced pulmonary hypertension (HPH), E2 attenuates lung …

Although extensively used for the study of left ventricular function, limited experience exists
with the isolated heart model in the evaluation of right ventricular (RV) function. In particular …

There is now ample evidence that differences in sex and gender contribute to the incidence,
susceptibility, presentation, diagnosis, and clinical course of many lung diseases. Some …

We tested the hypothesis that suppression of epoxyeicosatrienoic acid (EET) metabolism via
genetic knockout of the gene for soluble epoxide hydrolase (sEH-KO), or female-specific …

Even though pulmonary arterial hypertension (PAH) is more prevalent in women, women
with PAH exhibit better right ventricular (RV) function, more favorable RV treatment …

Cardiovascular disease (CVD) is the leading cause of death and disability in Western
societies. The epidemiology, presentation, pathophysiology, and outcomes of CVD and its …

Pulmonary arterial hypertension (PAH) is a sexually dimorphic disease that affects women
more than men. Several pre-clinical and clinical studies identified 17β-oestradiol (E2), the …

Although the response of the right ventricle (RV) to the increased afterload is an important
determinant of the patient outcome, very little is known about the underlying mechanisms …